NCT04687982View on ClinicalTrials.gov

Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

January 8, 2020

Study Completion Date

January 8, 2020

Conditions

Bone Marrow Transplant InfectionBone Marrow Transplant ComplicationsGraft Vs Host DiseaseInfectionHematological Malignancy

Interventions

BIOLOGICAL

modified donor lymphocytes infusion (mDLI)

"The planned number of mDLI is 3.~1. Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~2. 4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~3. 4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."

Trial Locations (1)

20089

Istituto Clinico Humanitas, Rozzano

All Listed Sponsors

lead

Istituto Clinico Humanitas

OTHER